外周血中性粒细胞/淋巴细胞比值与真性红细胞增多症血栓事件关系的研究

牛园满; 李振宇; 邱婷婷; 张焕新; 孙海英; 桑威; 程海; 黄一虹; 徐开林; 李德鹏

doi:10.13201/j.issn.1004-2806.2021.03.010

外周血中性粒细胞/淋巴细胞比值与真性红细胞增多症血栓事件关系的研究

- 徐州医科大学附属医院血液科(江苏徐州, 221000)
基金项目:
江苏省卫生厅科研基金项目(No:H201629)

详细信息

通讯作者: 李德鹏,E-mail:Lidepeng30@163.com

中图分类号: R555.1

收稿日期: 2020-11-05

Study on the relationship between peripheral blood neutrophil/lymphocyte ratio and thrombotic events in polycythemia eukaryotes

- Department of Hematology, Xuzhou Medical University, Xuzhou, 221000, China

More Information

Corresponding author: LI Depeng, E-mail: Lidepeng30@163.com

Received Date: 05 November 2020

摘要

摘要: 目的:探讨外周血中性粒细胞/淋巴细胞比值(NLR)对真性红细胞增多症(PV)患者初诊时血栓事件及未来血栓事件进展的相关性研究。方法:收集2013年1月—2020年8月本院PV患者的临床及随访资料,分析PV患者血栓事件的危险因素。结果:Logistic多因素分析发现,高血压、白细胞计数>10×10⁹/L是初诊PV患者血栓事件独立预测因素;未来血栓事件进展的预测与年龄(P<0.05),NLR(P<0.05),初诊时血栓病史(P<0.05),脾肿大(P<0.05)相关;ROC曲线表明,NLR与年龄、初诊时血栓史及脾肿大等临床参数相比更能预测未来血栓事件;Kaplan-Meier生存分析结果表明,高NLR组(NLR≥9.218)96个月血栓无进展总生存率为24.7%,而低NLR组(NLR<9.218)血栓无进展总生存率为92.0%。结论:PV患者外周血NLR水平对未来血栓事件进展具有预测价值,但与初诊时已形成的血栓事件无明显相关性。NLR可作为未来血栓事件进展预测指标之一,具有重要临床意义。
- 中性粒细胞与淋巴细胞比值 /
- 真性红细胞增多症 /
- 血栓
Abstract: Objective: To explore the correlation between peripheral blood neutrophil to lymphocyte ratio(NLR) and thrombotic events in patients with polycythemia vera(PV).Methods: We collected the clinical and follow-up data of PV patients in our hospital from January 2013 to August 2020, and analyze the risk factors of thrombotic events in patients with PV.Results: Logistic multivariate analysis showed that hypertension and white blood cell count>10×10⁹/L were independent predictors of thrombotic events in newly diagnosed PV patients; the progression of future thrombotic events was correlated with age(P<0.05), NLR(P<0.05), history of thrombosis at initial diagnosis(P<0.05), splenomegaly(P<0.05). ROC curve showed that NLR was more predictive of future thrombotic events than age, history of thrombosis and splenomegaly. The results of Kaplan-Meier survival analysis showed that high NLR group(NLR≥9.218) had 24.7% thrombosis progression free survival rate, while the low NLR group(NLR<9.218) had 92.0% overall survival rate.Conclusion: The level of NLR in peripheral blood of patients with PV at initial diagnosis has predictive value for the development of future thrombotic events, but there is no significant correlation between NLR level and thrombotic events. NLR can be used as one of the indicators to predict the progress of thrombotic events in the future, which has important clinical significance.
- neutrophil to lymphocyte ratio /
- polycythemia vera /
- thrombosis

HTML全文

参考文献(26)

[1]	McMullin MF,Harrison CN,Ali S,et al.A guideline for the diagnosis and management of polycythaemia vera[J].Br J Haematol,2019,184(2):176-191.
[2]	Hasselbalch HC.Perspectives on chronic inflammation in essential thrombocythemia,polycythemia vera,and myelofibrosis:is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?[J].Blood,2012,119(14):3219-3225.
[3]	Lussana F,Rambaldi A.Inflammation and myeloproliferative neoplasms[J].J Autoimmun,2017,85:58-63.
[4]	Hao Y,Qi Z,Ding Y,et al.Effect of Interventional Therapy on IL-1β,IL-6,and Neutrophil-Lymphocyte Ratio(NLR)Levels and Outcomes in Patients with Ischemic Cerebrovascular Disease[J].Med Sci Monit,2019,25:610-617.
[5]	张林,陈玥,张宝红,等.血小板-淋巴细胞比率、中性粒细胞-淋巴细胞比率及红细胞分布宽度在冠心病严重程度中的诊断价值[J].临床心血管病杂志,2020,36(9):824-827.
[6]	刘伟倩,齐晓勇.绝经后女性冠心病患者中性粒细胞/淋巴细胞比值与冠状动脉病变程度的相关性研究[J].临床心血管病杂志,2019,35(4):370-373.
[7]	张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:87-92.
[8]	Landolfi R,Cipriani MC,Novarese L.Thrombosis and bleeding in polycythemia vera and essential thrombocythemia:pathogenetic mechanisms and prevention[J].Best Pract Res Clin Haematol,2006,19(3):617-633.
[9]	Lengfelder E,Merx K,Hehlmann R.Diagnosis and therapy of polycythemia vera[J].Semin Thromb Hemost,2006,32(3):267-275.
[10]	Kroll MH,Michaelis LC,Verstovsek S.Mechanisms of thrombogenesis in polycythemia vera[J].Blood Rev,2015,29(4):215-221.
[11]	Tan X,Shi J,Fu Y,et al.Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation[J].Thromb Haemost,2013,109(6):1025-1032.
[12]	Aksu K,Donmez A,Keser G.Inflammation-induced thrombosis:mechanisms,disease associations and management[J].Curr Pharm Des,2012,18(11):1478-1493.
[13]	Köse N,Yildirim T,Akin F,et al.Prognostic role of NLR,PLR,and LMR in patients with pulmonary embolism[J].Bosn J Basic Med Sci,2020,20(2):248-253.
[14]	Kaya H,Ertas F,Islamoglu Y,et al.Association between neutrophil to lymphocyte ratio and severity of coronary artery disease[J].Clin Appl Thromb Hemost,2014,20(1):50-54.
[15]	Akyel A,Yayla C,Erat M,et al.Neutrophil-to-lymphocyte ratio predicts hemodynamic significance of coronary artery stenosis[J].Anatol J Cardiol,2015,15(12):1002-1007.
[16]	Hacibekiroglu T,Akinci S,Basturk A,et al.Evaluation of Inflammation Parameters in Philadelphia Negative Chronic Myeloproliferative Neoplasia Patients[J].Asian Pac J Cancer Prev,2015,16(13):5159-5162.
[17]	Kocak MZ,Daglı M,Ünlü A.The ratio of platelet/lymphocyte,the ratio of neutrophil/lymphocyte and some haemogram parameters related to thrombosis in essential thrombocytosis and polycythaemia vera[J].Biomed Res,2017,28(7):3036-3039.
[18]	Landolfi R,Di Gennaro L,Barbui T,et al.European Collaboration on Low-Dose Aspirin in Polycythemia Vera(ECLAP).Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera[J].Blood,2007,109(6):2446-2452.
[19]	Barbui T,Masciulli A,Marfisi MR,et al.White blood cell counts and thrombosis in polycythemia vera:a subanalysis of the CYTO-PV study[J].Blood,2015,126(4):560-561.
[20]	Elliott MA,Tefferi A.Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia[J].Br J Haematol,2005,128(3):275-290.
[21]	韩雪,白贝贝,王春健,等.真性红细胞增多症和原发性血小板增多症患者发生再次血栓事件的危险因素分析[J].中华血液学杂志,2019,40(1):17-23.
[22]	Accurso V,Santoro M,Raso S,et al.Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera:A single center study[J].Hematol Rep,2019,11(4):8281.
[23]	Stein BL,Oh ST,Berenzon D,et al.Polycythemia Vera:An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F[J].J Clin Oncol,2015,33(33):3953-3960.
[24]	Hexner EO.JAK2 V617F:implications for thrombosis in myeloproliferative diseases[J].Curr Opin Hematol,2007,14(5):450-454.
[25]	Borowczyk M,Wojtaszewska M,Lewandowski K,et al.The JAK2V617Fmutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms[J].Thromb Res,2015,135(2):272-280.
[26]	Iványi JL,Marton E,Plander M.A JAK2V617F-mutációjelent7sége krónikus myeloproliferative neoplasiás betegeinkben[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia][J].Orv Hetil,2011,152(45):1795-1803.